球探体育比分app下载 www.midjq.com.cn Introduction of NAFLD and NASH
       Nonalcoholic fatty liver disease (NAFLD) is defined as lipid-deposit accumulation in the hepatocytes, which is not due to excessive alcohol use. NAFLD encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which in its most severe form can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The NAFLD disorder has a prevalence of 15–20% in the general population and 76–90% in the obese. It is estimated that more than 1/3 of the population worldwide will be a risk in NAFLD, which is significantly exceeding an incidence of Hepatitis B, Hepatitis C, and Alcoholic Liver Disease. NAFLD is now the most common disease of the Liver.

Innovative Candidate Compounds for NASH treatment
        
ABP-6016 is a novel drug candidate for NASH treatment . It is expected to be a new generation of innovative medicine for NASH treatment.

{ganrao} 日本成人电影 日本av成人情色电影网 老快3 000880潍柴重机新闻 2009年中国股票指数 快速时时彩 足彩进球彩 今日上证指数是多少点 新闻 保利地产股票分析报告 股票配资1配资658 新浪体育手机新浪网一 宫濑里子 新浪体育电竞 一级日本黄色片 山东群英会 海南飞鱼